Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

Smruthi Organics Limited

Healthcare › Pharmaceuticals & Biotechnology
₹158.00
at close · 8 Oct 2026
▲ 2.00 (+1.28%)

Latest filings

  1. CG approves Ms Smruthi Eaga as Whole-time Director for three years · Management Changes
  2. Compliance certificate for Q2 FY27 dematerialisation · Compliance
  3. Trading Window Closed for Q2 Results Period · Compliance
All filings ↓
Ask Nexa about Smruthi Organics Limited

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures Active Pharmaceutical Ingredients (APIs) at a facility in the Solapur area, with API accounting for essentially all of FY26 revenue and a negligible Formulation line. The portfolio includes products such as Amlodipine Besilate, a blood-pressure ingredient, for which the company received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM). An EDQM GMP attestation has also been issued for the manufacturing site, enabling supply to European and other regulated markets. International marketing activity covers Central and South American markets. FY26 total revenue was Rs 101.97 crore, down from Rs 125.65 crore in FY25, with net profit of Rs 3.43 crore. The largest cost line is materials at 44.4% of revenue, followed by employee cost at 17.2% and other operating expenses at 25.5%. Capex in FY26 was Rs 8.47 crore (8.3% of revenue), and the balance sheet carries very little debt, with a debt-to-equity ratio of 0.11.

Operating scale
FY26 total revenue
Rs 101.97 croreFY26
FY26 API quarterly revenue (Q4)
Rs 29.09 croreQ4 FY26
FY26 capex
Rs 8.47 crore (8.3% of revenue)FY26
EDQM CEP certification
Certificate of Suitability granted for Amlodipine BesilateMarch 2026
EDQM GMP attestation
Attestation of Inspection received for manufacturing facilityMarch 2026
International marketing reach
Central and South American marketsSince FY22
Who pays it
Pharmaceutical manufacturers in domestic India, Europe and other regulated markets, plus Central and South American buyers (B2B ingredient sales).
Biggest cost
Raw materials and chemicals, at 44.4% of FY26 revenue.
Kind of business
Small, low-leverage, B2B API manufacturer with regulated-market certifications.
Where it sits
Single-product-line pharma company whose API segment accounted for effectively the entire FY26 revenue, with Formulation contributing negligibly.
Market Cap
₹181 Cr
P / E (TTM)
52.8×
EV / EBITDA
14.8×
Div Yield
0.95%
Growth
-4.2%▼
Revenue 5y CAGR
PAT -27.5% · EBITDA -15.3%
Quality
8.4%·
ROCE (5y median)
ROE 5.2% (5y median) · margin 12.5%
Leverage
0.11·
Debt / Equity · low
Net debt ₹6.66 Cr
Revenue FY21→FY26
0.8×▼
Margin −10.2 pts
₹127 Cr → ₹102 Cr
Cash conversion
2.02×▲
Operating cash ÷ profit · 5 yrs
₹51 Cr on ₹25 Cr
Moves on a normal day
1.50%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#118/158
P/B#68/163
ROCE#120/183
ROE#118/166
Debt / Equity#77/166
EBITDA margin#102/165
Revenue growth#144/161
Profit growth#134/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Over 5 years it reported ₹25 Cr of profit and ₹51 Cr of operating cash — 2.02×
Profit is converting into cash
Pays out 50% of profit as dividend
Concerns
Revenue shrinking over 5 years (−4% a year)
Profit shrinking over 5 years (−28% a year)
Erratic profits — up in only 0 of the last 5 years
Heavy working capital — 121 days of cash tied up

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from Smruthi Organics Limited's filed financials and exchange disclosures

What does Smruthi Organics Limited do?

Smruthi Organics Limited is a Pharmaceuticals & Biotechnology company listed on BSE.

Is Smruthi Organics Limited profitable?

Yes. Over the trailing twelve months Smruthi Organics Limited reported a net profit of ₹3.43 Cr on revenue of ₹102 Cr.

Does Smruthi Organics Limited pay a dividend?

Yes. The dividend yield is 0.95% at the current price. It paid out 50% of its profit as dividend in FY26.

Is Smruthi Organics Limited debt-free?

No. It reported borrowings of ₹8.37 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹6.66 Cr after cash. Debt stands at 0.11× equity. That is lower than 54% of its 166 Pharmaceuticals peers.

Is Smruthi Organics Limited expensive compared with its peers?

On trailing P/E, Smruthi Organics Limited ranks 118 of 158 in Pharmaceuticals — cheaper than 26% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.

How much does the Smruthi Organics Limited share price move in a day?

On a typical session Smruthi Organics Limited moves 1.50% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track Smruthi Organics Limited's announcements?

Every NSE and BSE filing by Smruthi Organics Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.